GSK reports positive outcomes from Phase III multiple myeloma treatment trial
The head-to-head, randomised, multi-centre trial enrolled 494 subjects.
15 November 2024
15 November 2024
The head-to-head, randomised, multi-centre trial enrolled 494 subjects.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.